Featured Research

from universities, journals, and other organizations

Antidepressant holds promise in treating Alzheimer's agitation

Date:
February 18, 2014
Source:
Johns Hopkins Medicine
Summary:
The antidepressant drug citalopram, sold under the brand names Celexa and Cipramil and also available as a generic medication, significantly relieved agitation in a group of patients with Alzheimer’s disease. In lower doses than those tested, the drug might be safer than antipsychotic drugs currently used to treat the condition, according to results of a clinical trial that included eight academic medical centers in the United States and Canada.

The antidepressant drug citalopram, sold under the brand names Celexa and Cipramil and also available as a generic medication, significantly relieved agitation in a group of patients with Alzheimer's disease. In lower doses than those tested, the drug might be safer than antipsychotic drugs currently used to treat the condition, according to results of a clinical trial led by Johns Hopkins researchers that included seven other academic medical centers in the United States and Canada.

For the study, reported in the Feb. 19 issue of the Journal of the American Medical Association, Constantine Lyketsos, M.D., M.H.S., and his colleagues recruited 186 patients with Alzheimer's who showed a collection of symptoms including emotional distress, excessive movement, aggression, disruptive irritability and disinhibition. None experienced adequate symptom relief with non-medical therapies, and some experienced failed treatment with antipsychotic drugs. Though antipsychotics are often used as first-line medications for Alzheimer's-related agitation, they significantly increase the risk of strokes, heart attacks and death, Lyketsos says.

At the start of the study, patients also underwent tests to define the extent of their agitation, memory and other cognitive skills, and their caregivers' stress levels, a factor strongly linked to the well-being of those with Alzheimer's. The patients were then separated into two groups. For the next nine weeks, about half took increasing doses of citalopram that peaked at 30 milligrams per day, and the rest took an identical-looking placebo.

At the end of the study period, the same set of tests was given, along with electrocardiograms. The study drug is linked to adverse effects on heart function, including irregular heartbeat, a harbinger of a heart attack.

Results showed that patients on the drug had significant relief from their agitation symptoms, Lyketsos says. In one measure of agitation, about 40 percent of patients who took citalopram had "considerable relief," compared to 26 percent of patients who took the placebo. The caregivers for these patients reported less stress.

However, patients on the drug were also more likely to have slightly decreased cognitive function. "It was not huge, but measureable," says Lyketsos, director of the Johns Hopkins Memory and Alzheimer's Treatment Center and director of the Department of Psychiatry at Johns Hopkins Bayview Medical Center. "That introduces a tradeoff."

More concerning, he adds, is that patients on citalopram had longer QTc intervals, a measure of abnormal heart function that increases the risk of heart attacks. However, Lyketsos says, antipsychotic medications also used to treat agitation increase heart attack risk as well, perhaps even more substantially.

Lyketsos and his colleagues hope to test if a lower dose of citalopram might be just as effective in treating Alzheimer's-related agitation with less risk for cognition and heart function. In the meantime, he says, the drug offers an alternative to antipsychotics.

"If the agitation is not responding to non-medication treatments and your patient's agitation isn't improving, there are no great options," Lyketsos says. "But here's another medication choice that might be safer than other medications and seems to be just as effective."


Story Source:

The above story is based on materials provided by Johns Hopkins Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Anton P. Porsteinsson, Lea T. Drye, Bruce G. Pollock, D. P. Devanand, Constantine Frangakis, Zahinoor Ismail, Christopher Marano, Curtis L. Meinert, Jacobo E. Mintzer, Cynthia A. Munro, Gregory Pelton, Peter V. Rabins, Paul B. Rosenberg, Lon S. Schneider, David M. Shade, Daniel Weintraub, Jerome Yesavage, Constantine G. Lyketsos. Effect of Citalopram on Agitation in Alzheimer Disease. JAMA, 2014; 311 (7): 682 DOI: 10.1001/jama.2014.93

Cite This Page:

Johns Hopkins Medicine. "Antidepressant holds promise in treating Alzheimer's agitation." ScienceDaily. ScienceDaily, 18 February 2014. <www.sciencedaily.com/releases/2014/02/140218163051.htm>.
Johns Hopkins Medicine. (2014, February 18). Antidepressant holds promise in treating Alzheimer's agitation. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2014/02/140218163051.htm
Johns Hopkins Medicine. "Antidepressant holds promise in treating Alzheimer's agitation." ScienceDaily. www.sciencedaily.com/releases/2014/02/140218163051.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins